DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors

To evaluate the safety and efficacy of DCSZ11 in combination with standard therapy in patients with advanced or metastatic solid tumors.

Trial Details

NCT ID
NCT07035249
Phase
PHASE1 / PHASE2
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Low Dose DCSZ11
  • Medium Dose DCSZ11
  • High Dose DCSZ11
  • Standard Treatment
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Male or female patients aged ≥18 years.
  • Willing and able to provide written informed consent for the study.
  • Patients with histologically confirmed advanced or metastatic solid tumors. Note: Patients must have guideline-eligible standard chemotherapy and i…
  • Patients must have at least one measurable lesion per RECIST 1.1 criteria. Lesions located in previously irradiated areas may be considered measura…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →